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Abstract
Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic 
shock syndrome. Dengue vaccine development is challenging because of the need to
induce protection against four antigenically distinct DENV serotypes. Recent studies indi-
cate that tetravalent DENV vaccines must induce balanced, serotype-specific neutralizing 
antibodies to achieve durable protective immunity against all 4 serotypes. With the leading
live attenuated tetravalent DENV vaccines, it has been difficult to achieve balanced and 
type-specific responses to each serotype, most likely because of unbalanced replication of 
vaccine viral strains. Here we evaluate a tetravalent DENV protein subunit vaccine, based 
on recombinant envelope protein (rE) adsorbed to the surface of poly (lactic-co-glycolic
acid) (PLGA) nanoparticles for immunogenicity in mice. In monovalent and tetravalent for-
mulations, we show that particulate rE induced higher neutralizing antibody titers compared 
to the soluble rE antigen alone. Importantly, we show the trend that tetravalent rE adsorbed 
to nanoparticles stimulated a more balanced serotype specific antibody response to each 
DENV serotype compared to soluble antigens. Our results demonstrate that tetravalent 
DENV subunit vaccines displayed on nanoparticles have the potential to overcome unbal-
anced immunity observed for leading live-attenuated vaccine candidates.
Author summary
Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic
fever. Yearly, over 350 million individuals in over 120 countries are infected. To establish
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protection through vaccination, one must induce simultaneous immunity against four
antigenically distinct DENV serotypes. However, this is challenging because it has been
shown that vaccination can enhance disease due to specific immunity to the virus. As an
alternative to existing vaccine platforms, we are exploring the potential of a protein sub-
unit vaccine using only the DENV envelope protein (E) as the vaccine antigen. To increase
the immunogenic potency of E, we attach it to nanoparticle carriers. For each individual
DENV serotype, we show that we can enhance immune responses in monovalent as well
as tetravalent formulations when E is attached to nanoparticles. Additionally, in tetrava-
lent nanoparticle formulations, vaccine quality is increased by the generation of a more
balanced serotype specific immune antibody response to each DENV serotype. The nano-
particle vaccine platform described here for DENV vaccines serves as a promising and
safe alternative to more conventional vaccine platforms and can be modified to develop
vaccines for other viral pathogens such as West Nile, yellow fever virus or Zika virus.
Introduction
The four dengue virus (DENV) serotypes are the causative agent of dengue fever and dengue
hemorrhagic fever. DENVs are transmitted by Aedes sp. mosquitoes and both virus and vector
are widely distributed throughout all tropical and subtropical regions, resulting in an estimated
300 million new infections per year, and approximately 1 million cases of severe disease with a
case fatality 2–5% [1]. DENVs are endemic in over 125 countries and about 40% of the world’s
population is at risk of getting infected by one of the 4 DENV serotypes. Primary infections
induce robust and long term protective immunity against the serotype of infection, but indi-
viduals remain susceptible to one of the other serotypes. People experiencing secondary het-
erotypic infections are at greater risk of developing severe disease. Under some conditions,
DENV serotype cross-reactive and poorly neutralizing antibodies induced after the primary
infection, appear to enhance the second infection via the formation of virus-antibody com-
plexes that promote infection of Fc-receptor bearing human myeloid cells [2,3]. It has been
challenging to control the main mosquito vector of DENV. There are no effective antiviral or
other therapies to treat DENV infections [4].
Based on success with other flaviviruses such as yellow fever and Japanese encephalitis
viruses, vaccination is a promising strategy for dengue prevention and control. As effective
immunity to just one serotype may place people at risk of severe disease upon infection with a
different serotype, leading vaccine candidates are based on tetravalent live-attenuated virus
formulations. In December 2015, the first DENV tetravalent vaccine, Dengvaxia developed by
Sanofi Pasture, was licensed by several countries. However, long-term data from Dengvaxia
clinical trials indicate that the vaccine is only effective in people who have already been primed
by natural DENV infections before vaccination. Naïve individuals who have received the vac-
cine appear to face a greater risk of developing severe disease upon exposure to wild type
DENVs and the vaccine is now recommended for use only in people with pre-existing immu-
nity to DENVs [5–10].
As an alternative to inactivated or live attenuated whole virus formulations, several groups
have focused on using recombinant DENV envelope (E) protein (rE) as a vaccine antigen [11–
15]. Even though single soluble subunits are generally not immunogenic in primates [16],
studies have shown that the immunogenicity of rE subunits can be augmented when combined
with potent adjuvants or carriers [15,17,18]. We have previously demonstrated that adsorbing
DENV2 rE to the surface of 80x320 nm particle replication in non-wetting templates (PRINT)
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produced poly(lactic-co-glycolic acid) (PLGA)-nanoparticles outperformed soluble rE sub-
units in terms of DENV2 specific IgG titers and neutralizing antibody titers [15]. The use of
nanocarriers composed of biodegradable polymers not only creates an antigen depot and
enhances antigen immunogenicity by effectively targeting antigen-presenting cells, but it pro-
vides a platform with the potential to mimic structural and antigenic features of the pathogen
[19–22]. Here we demonstrate that a tetravalent DENV E protein formulation of PLGA nano-
particles induced higher levels of serotype specific IgG and neutralizing antibody titers than
soluble tetravalent rE formulations in mice.
Materials and methods
Cells and viruses
Vero cells (American Type Culture Collection (ATCC)) were maintained as monolayer cul-
tures in DMEM medium (Gibco) supplemented with 1% non-essential amino acids, 5% fetal
bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin at 37˚C with 5% CO2.
EXPI293 cells (Gibco) were maintained in suspension culture in EXPI293 Expression Medium
(Life Technologies) and were passaged 1:10 when cell densities reached 3.5×106 cells/ml.
To determine (neutralizing) antibody titers, DENV1 WestPac-74, DENV2 S-16803,
DENV3 CH53489 and DENV4 TVP-376 were used.
Recombinant E protein expression and purification
The recombinant E (rE) proteins of DENV1 (aa 1–397), DENV2 (aa 1–395), DENV3 (aa 1–395)
and DENV4 (aa 1–397) were expressed by the EXPI293 transient expression system (Thermo-
Fisher) following supplied protocols. The previously described expression construct was used [15]
where an N-terminal IL2 secretion peptide leads the homotypic prM-rE cassette for each serotype.
All rE proteins were equipped with a C-terminal 6×His-tag (SSGGSHHHHHH). Protein expres-
sion was driven by a CMV early enhancer β-actin promoter.
Recombinant proteins were purified as previously described [15]. In short, expression
supernatants were concentrated and buffer exchanged by tangential flow filtration and pro-
teins were purified by Ni2+-affinity chromatography. Elution fractions containing the rE-pro-
teins were pooled and subjected to size-exclusion chromatography. Finally, the purified and
concentrated proteins were flash frozen and stored at -80˚C until further use.
Protein analysis
Purified rE proteins were subjected to SDS-PAGE and analyzed by Western Blot (WB) and
Coomassie Brilliant Blue (CBB) staining. 500 ng of DENV1 rE and 1μg of DENV2, 3 and 4 rE
was added to a denaturing gel loading buffer containing SDS. Separated protein fraction were
transferred to a nitrocellulose membrane and blocked overnight at 4˚C with TBS+3% Skim
Milk + 0.05% Tween-20. Next, the membranes were treated with 0.5 μg/ml 1M7 human mAb
in blocking buffer for 1 hr at 37˚C. After washing, the membranes were subjected to 1:1000
diluted AP-conjugated anti-human IgG for 1 hr at 37˚C and membranes were subsequently
washed. Finally, membranes were developed using NBT/BCIP substrate (ThermoScientific)
and the reaction was terminated in MilliQ water.
Protein confirmation analysis by antigen capture ELISA
Ni2+-coated ELISA plates (Pierce) were used to capture 2 ng/μl (in TBS) rE proteins (DENV1-
4) for 1 hr at 37˚C. The plates were blocked using TBS + 3% skim milk + 0.05% Tween-20 for
1 hr at 37˚C and subsequently washed 3 times with TBS + 0.05% Tween-20. Next, plates were
incubated for 1 hr at 37˚C with 2 ng/μl (in blocking buffer) of mouse and human derived
mAbs: 4G2 (mouse, cross-reactive), 3H5 (mouse, DENV2 specific), 12C1.5 (mouse, cross-
reactive), 8A1 (mouse, DENV3 specific), 1M7 (human, cross-reactive), 1F4 (human, DENV1
specific), 2D22 (human, DENV2 specific), 5J7 (human, DENV3 specific), 5H2 (chimpanzee,
DENV4 specific) and DV4 141 (human, DENV4 specific) (Table 1). Following incubation, the
plates were washed and accordingly treated with AP-conjugated anti-mouse IgG (Sigma,
1:1000) or AP-conjugated anti-human IgG (Sigma, 1:2500) for 45 mins at 37˚C. Finally, the
plates were washed, developed with AP-substrate (Sigma) and absorbance was measures at 405
nm.
PLGA nanoparticle fabrication and formulation
PRINT technology was used to manufacture 80×320 nm poly (lactic co-glycolic acid) (PLGA,
50:50, 35 kDa, Lakeshore Biomaterials) particles as previously described [34,35]. In short,
PLGA and DC-cholesterol (Avanti Polar Lipids) were dissolved in chloroform (9:1 w/w ratio)
and casted into a thin film on a PET-sheet (KRS Plastics). The film was oriented in order to
contact the molds and carefully heated. Next, the film was split and the mold content was
transferred to a second PET-sheet by passing through a laminator. Then water with 0.1% poly-
vinyl alcohol (PVOH) was added to the PET-sheet to release the nanoparticles (NPs). The har-
vested particles were sterilized and concentrated by sterile filtration and tangential flow
filtration.
To adsorb the rE proteins to NP surfaces, rE was incubated with PLGA NPs in a 1% rE/NP
(w/w%) ratio for 15 mins at room temperature in 0.1% PVOH in water with 9.25% sucrose to
establish 100% adsorption efficiency for all serotypes.
Mouse immunizations
Female Balb/c mice were purchased from Jackson Laboratory and used at 6–12 weeks of age.
For the monovalent formulations of every serotype, each mouse was immunized subcutane-
ously in the flank with 5 μg soluble rE (n = 5), 5 μg rE+500 μg Alum (n = 5), PBS (Vehicle
n = 3) or 5 μg adsorbed to 500 μg PLGA-NPs (n = 5). DENV2 immunization were previously
described, but were included to generate complete overview [15].
Table 1. Dengue specific monoclonal antibodies.




Binding DENV serotypes Ref
DV1 DV2 DV3 DV4 ZIKV
4G2 M F-CR W DII FL ++ ++ +++ +++ +++ [23]
1F4 H DV1 DV1:S DI/DII hinge Q +++ - - - - [24]
12C1.5 M D-CR DV:S DIII ++ ++ +++ ++ - [25]
2D22 H DV2 DV2:S ZIKV:W DII/DIII Q - ++ - - - [26,27]
5J7 H DV3 DV3:S DI/DII Q - - +++ - - [28]
5H2 C DV4 DV4:S DI Q - - - + - [29]
1M7 H F-CR M DII FL +++ ++ +++ +++ +++ [30]
3H5 M DV2 DV2:S DIII LR - +++ - - - [31]
8A1 M DV3 DV3:S DIII - - +++ - - [32]
DV4 141 H DV4 None DIII - - - +++ - [33]
A panel of well-defined mouse, human or chimpanzee (M/H/C) derived Mabs were used in this study. Flavivirus cross reactive (F-CR), dengue cross reactive (D-CR),
weakly, moderately or strong (W/M/S) neutralizing, E-domain I, II, III (DI, DII, DIII), fusion loop (FL), lateral ridge (LR), quaternary (Q).
https://doi.org/10.1371/journal.pntd.0006793.t001
The tetravalent formulation were divided into 2 groups. The tetra rE group (TR) combined
5 μg soluble rE of each serotype (n = 5). The NP-tetra rE group (NTR) is composed of 500 μg
NPs combined with a mix of the four rE serotypes (NP+rEDENV1-4 (5 μg each, n = 5)). The
tetra NP-rE group (TNR) combines four individually adsorbed NP-rE formulations of each
DENV serotype (NP-rEDENV1 + NP-rEDENV2 + NP-rEDENV3 + NP-rEDENV4 (500 μg NPs
+ 5 μg rE)). All groups in both the monovalent and tetravalent studies were immunized with
the same antigen dose at day 0, 21 and 63 and serum samples were collected at indicated time
points.
Vaccine induced antibody evaluation
ELISA plates were coated overnight with 2 ng/μl 1M7 in 50mM carbonate/bicarbonate buffer
at 4˚C. The following day, the plates were blocked with TBS + 3% skim milk + 0.05% Tween-
20 for 1 hr at 37˚C. Next, the plates were washed in TBS + 0.05% Tween-20 and incubated
with DENV2 or 2 ng/μl rE in blocking buffer for 1 hr at 37˚C. After washing, the immunized
mice sera of week 3, 4, 8, 10 and 16 were diluted 1:50 in blocking buffer and week 16 sera was
also serially diluted in blocking buffer and loaded onto the plate for 1 hr at 37˚C. Next, the
plates were washed and incubated with AP-conjugated anti-mouse IgG (Sigma, 1:1000 in
blocking buffer), IgG1 (Abcam, 1:2500) or IgG2a (Abcam, 1:2500) for 45 mins at 37˚C. The
plates were developed after washing with AP-substrate (Sigma) and absorbance was measured
at 405 nm. The end point dilution (EPD) where the immunized mice sera reached background
levels was determined using GraphPad Prism software.
Evaluation of neutralizing antibody responses in immunized mice sera
The previously described Vero-cell based flow cytometry neutralization assay was used to mea-
sure DENV serotype specific neutralizing antibodies [15,36]. In brief, Vero cells (25000/well)
were seeded and incubated overnight at 37˚C. The next day, immunized mice sera was serially
diluted in OptiMEM (Gibco) supplemented with 2% FBS and incubated with the appropriate
amount of virus to infect ~15% of the cells (amount previously determined) for 45 mins at
37˚C. Next, the cells were washed with OptiMEM and overlaid with the virus-serum combina-
tion for 2 hr at 37˚C. Following incubation, the cells are washed with growth medium and
incubated overnight in 200 μl growth medium at 37˚C. Next, the cells are washed with PBS
and detached from the plates by trypsin (Gibco). Detached cells are transferred to a round-bot-
tom plate and fixed with 4% paraformaldehyde for 10 mins at room temperature. The cells are
washed in permeabilization buffer and blocked 1% normal mouse serum in perm buffer for 30
mins at room temperature. Next, the cells were incubated with Alexa-fluor 488 conjugated
anti-prM mAb 2H2 for 1 hr at 37˚C. After washing in perm buffer, the cells were resuspended
in 200 μl FACS buffer. The percentage of infected cells was determined by flow cytometry
using the Guava Flow Cytometer (EMD Millipore) and the neutralizing capacity was deter-
mined by GraphPad Prism and expressed in neut50 values (the dilution where 50% of the virus
was neutralized).
IgG depletion of immunized mice sera by recombinant E proteins
Serum from 5 immunized mice was pooled for each tetravalent group and the serotype specific
and cross-reactive IgG populations were depleted using immobilized homo- and heterotypic
rE proteins. First, 1 mg of HisPur Ni-NTA magnetic beads (ThermoFisher) was washed and
equilibrated using PBS + 10mM imidazole. Equilibrated beads were incubated with 40 μg of rE
or MBP-His proteins (control depletions) for 30 mins at 37˚C on a rotator. The beads were
placed in a magnetic stand and were washed 3 times with washing buffer and finally divided
over 2 tubes for two rounds of depletion. Next, 400 μl of 1:10 diluted (PBS) pooled sera was
incubated with the chelated rE-beads for 1 hr at 37˚C. The beads were placed in a magnetic
stand and the sera was transferred for the second round of depletion for 1 hr at 37˚C. The
depleted serum was separated from the beads and stored at 4˚C for subsequent IgG ELISAs
and neutralization assays. The percentage of type specific neutralizing antibodies in Table 2
was determined by dividing the type specific neut50 (CR depl.) by the control neut50 (Ctrl
depl.).
Ethics statement
All experiments involving mice were performed according to the animal use protocol (IACUC
ID:17–047) approved by the University of North Carolina Animal Care and Use Committee.
The animal care and use related to this work complied with federal regulations: the Public
Health Service Policy on Humane Care and Use of Laboratory Animals, Animal Welfare Act,
and followed the Guide for the Care and Use of Laboratory Animals.
Results
Expression and characterization of recombinant E protein (rE) protein
from DENV1-4
The full prM sequence and the ectodomain of E of each DENV serotype was cloned down-
stream of an IL2 secretion signal sequence and expressed in EXPI293 cells (Fig 1A). All rE pro-
teins contained a C-terminal His-tag for purification and immobilization purposes. Analysis
of the purified rE samples by gel electrophoresis and Western Blotting established the proteins
were pure and of the predicted molecular mass of ~ 48kDa (Fig 1B). In addition to monomers,
rE dimers of ~ 100kDa were routinely detected. While the exact confirmation of this dimer is
unknown, DENV rE proteins have been shown to form a concentration and temperature
dependent dimer-monomer equilibrium [37,38].




Ctrl depl. (Neut50) TS depl. (Neut50) CR depl. (Neut50) TS neut
DV1 2398 912 50 53 6.1%
DV2 7244 3715 50 1819 49.6%
DV3 10232 4466 50 1891 41.2%
DV4 1778 1513 50 630 43.1%
TNR (NP-DV1 + NP-DV2 + NP-DV3 + NP-DV4)
Serotype Undepl.
(Neut50)
Ctrl depl. (Neut50) TS depl. (Neut50) CR depl. (Neut50) TS neut
DV1 1995 1174 50 257 22.8%
DV2 6918 2691 50 1000 37.8%
DV3 3090 2454 50 1318 54.8%
DV4 1258 562 50 501 97.8%
The proportions of serotype-specific and cross-reactive neutralizing antibody titers per DENV serotype in sera of mice immunized with tetravalent vaccine formulations
were evaluated using a DENV serum depletion assay. Serum was incubated with magnetic beads coated with rE of DENV1, 2, 3 or 4 and serotype specific neutralizing
IgG titers were determined against all 4 rE serotypes. The neutralizing capacity of undepleted (Undepl.), handling control sera (Ctrl depl.), serotype specific depleted (TS
depl.) and cross-reactive depleted (CR depl.) was expressed as Neut50 values and used to determine the percentage of serotype specific neutralizing antibodies (TS neut).
https://doi.org/10.1371/journal.pntd.0006793.t002
The DENV rE proteins were captured on Ni2+-coated ELISA plates using the C-terminal
His-tag and tested for binding to a panel of serotype specific or cross-reactive mAbs (Fig 1C).
The DENV cross-reactive mAbs 1M7 and 4G2 efficiently bound to all serotypes of rE. The
DENV type-specific mAbs 3H5 (DENV2), 8A1 (DENV3), DV4 141 (DENV4) that recognize E
protein epitopes on the monomer bound to each rE protein. DENV type-specific human
mAbs 1F4 (DENV1), 2D22 (DENV2) and 5J7 (DENV3) which bind to quaternary structure
epitopes displayed on the E homodimer or higher order structures showed marginal binding
to each cognate antigen indicating that the purified antigens were mainly present as monomers
[38].
DENV rE antigens adsorbed to nanoparticles are better immunogens than
soluble antigens
Mice were subcutaneously immunized with 5 μg of soluble rE alone, 5 μg of rE adsorbed to
80×320 PLGA NPs (Fig 2A) and 5 μg of rE with Alum (500 μg alum) on day 0 and then
boosted on week 3 and week 9 with the same vaccine formulation used to prime the animals.
DENV specific IgG levels were evaluated in sera collected on week 3, 4, 10 and 16, and neutral-
izing antibody titers were determined for week 16 serum samples (Fig 2B). The DENV1, 2 and
4 rE antigens adsorbed to nanoparticles stimulated higher mid-point dilution levels of specific
antibody compared to soluble antigens (Fig 3A). The antigens on nanoparticles and the solu-
ble antigens with Alum adjuvant induced similar levels of DENV-specific antibodies (Fig 3A).
The DENV3 rE appeared to be inherently immunogenic, since DENV3 rE alone induced high
levels of neutralizing antibodies that were not improved by particulation or the addition of the
adjuvant. As described previously, at week 16 the DENV2 rE on nanoparticles induced higher
Fig 1. Expression and characterization of DENV1-4 rE. A) Schematic representation of the DENV1-4 rE expression constructs. The ectodomain of DENV1-4 E was
expressed together with the homotypic prM protein, upstream an IL2 leader peptide. Recombinant proteins were equipped with a C-terminal His-tag and expressed
under control of a CAG promoter on a pαH-expression vector in EXPI293 cells. B) Purified rE was subjected to SDS-PAGE and analyzed with CBB and WB using a
1M7 human derived mAb. C) DENV1-4 rE purified proteins fractions were loaded on Ni2+-coated ELISA plates and analyzed with a panel of cross-reactive or serotype
specific mAbs (DENV1-1F4; DENV2-3H5, 2D22; DENV3-8A1, 5J7; DENV4-DV4 141, 5H2).
https://doi.org/10.1371/journal.pntd.0006793.g001
levels of neutralizing antibodies than the soluble antigen alone (Fig 3B) [15]. Mice that were
immunized with DENV1 or DENV4 rE on nanoparticles also had higher levels of neutralizing
antibodies compared to soluble antigen alone or with the alum adjuvant (Fig 3B). These results
establish that the immunogenicity of monovalent DENV1, 2 and 4 rE antigens is improved by
adsorption to 80 x 320 nm PLGA nanoparticles when compared to the soluble antigen alone.
The immunogenicity of tetravalent rE nanoparticle vaccines
Next, we assessed the immunogenicity of tetravalent formulations of rE from DENV1-4 in the
presence or absence of nanoparticles. Mice were immunized with a mixture of the 4 soluble rE
antigens (5 μg per antigen) alone (TR group), or with 5 μg of each antigen separately adsorbed
to 500 μg of PLGA NPs and then combined into a tetravalent mix (TNR group) (Fig 4). Mice
were immunized and boosted at week 3 and 9. Serum samples were collected at week 3, 4, 8, 10
and 16 to measure total DENV-specific IgG and functionally neutralizing antibody (week 16
only) (Fig 2A). Both tetravalent formulations induced DENV-specific IgG against all four
serotypes and antibody titers remained elevated through week 16 (7 weeks post 2nd boost) (Fig
5A). At week 16, the overall level of DENV2, 3 and 4 binding antibodies were higher in the
TNR group compared to the soluble TR group (Fig 5B). Soluble antigens predominantly
induced an IgG1 response, where the particulated antigen stimulate a more balanced IgG1/
IgG2a response (Fig 5B). The soluble and particulate formulation induced high levels of neu-
tralizing antibodies with no significant differences between groups (Fig 5C). Overall DENV1
neut50 titers were lower compared to the other serotypes due to large variation within groups
especially in the TR group.
The influence of nanoparticles on the quality of DENV neutralizing
antibodies induced by tetravalent rE vaccine
Recent data from a live-attenuated DENV vaccine clinical trials indicate that the quality rather
than the total quantity of DENV neutralizing antibodies is a better predictor of vaccine efficacy
Fig 2. NP-rE adsorption efficiency. A) rE proteins from all serotypes were individually adsorbed to the PLGA nanoparticles in variable srE/NP (w/w%) ratios.
Adsorption efficiency was determined by the amount of non-adsorbed rE after the spinning down the particles. B) Mice were immunized (subcutaneous) with 5 μg of
rE or 5 μg rE adsorbed to PLGA nanoparticles. Animals were boosted on day 21 and day 63 and serum samples were taken at indicated time points.
https://doi.org/10.1371/journal.pntd.0006793.g002
[39]. In particular, the level of DENV type-specific neutralizing antibody may be a better pre-
dictor of protective immunity than the total level of vaccine induced neutralizing antibody
(type-specific + cross-reactive) [39]. We performed studies to evaluate the type-specificity of
binding and neutralizing antibodies induced by soluble and nanoparticle delivered tetravalent
rE vaccines. Given the limited quantities of week 16 immune sera remaining after the primary
analysis, we had to pool the sera from the 5 mice in each group for these studies. To determine
the fraction of serotype specific IgG and neutralizing antibodies stimulated by each formula-
tion, the pooled immune sera from each group was depleted to remove total or just cross-reac-
tive antibodies to each serotype and tested for binding to rE from each serotype (Fig 6) and for
functional neutralization of each serotype (Fig 7, Table 2).
When DENV cross-reactive antibodies were depleted from immune sera collected from
mice that received the soluble TR formulation, the animals had type-specific antibodies
directed to epitopes on DENV2, 3 and 4 but not DENV1 (Fig 6A green bars). In the animals
Fig 3. Monovalent NP-rE formulations induce robust neutralizing antibody titers. A) DENV1-4 specific IgG titers were determined for week 3, 4, 10 and 16. B) The
neutralizing activity of the mice sera at week 16 was determined with a neutralization assay where DENV is incubated with serially diluted mice sera and subsequently
allowed to infect Vero-cells. Neutralizing activity was expressed as the dilution where 50% of the virus was neutralized (Neut50).
 DENV2 data adapted from previously
published data [15]. Statistical differences were determined by one-way ANOVA followed by Tukeys test (p<0.05).
https://doi.org/10.1371/journal.pntd.0006793.g003
Fig 4. Tetravalent DENV1-4 rE formulations. The tetravalent formulations were divided into 2 groups. The tetra rE
group (TR) combined 5 μg soluble rE of each serotype (n = 5). The tetra NP-rE group (TNR) combines four
individually adsorbed NP-rE formulations of each DENV serotype (NP-rEDENV1 + NP-rEDENV2 + NP-rEDENV3 + NP-
rEDENV4 (500 μg NPs + 5 μg rE).
https://doi.org/10.1371/journal.pntd.0006793.g004
that received rE antigens adsorbed to nanoparticles, we observed type-specific antibodies to all
4 serotypes (Fig 6B green bars).
Depletions with the homologous rE of each serotype efficiently removed all neutralizing
antibodies from mice immunized with each tetravalent formulation (Fig 7, red lines). In the
TR group (soluble tetravalent antigen), the animals had high levels of type-specific neutralizing
antibodies to DENV2, 3 and 4 but the DENV1 neutralizing antibody response was mainly
derived from cross-reactive antibodies (Fig 7A, green line; Table 1). In contrast, in the TNR
group the animals developed robust type-specific neutralizing antibody responses to all 4 sero-
types (Fig 7B, green line; Table 2). The magnitude of the type-specific neutralizing antibody
response was greater for both DENV4 and DENV1 in the TNR group compared to the TR
group (Table 2). The DENV2 and 3 responses had similar levels of type-specific neutralizing
antibodies in both the TR and TNR groups. Our results indicate that nanoparticle delivery of a
tetravalent rE antigen mix stimulates a more balanced type-specific neutralizing antibodies
compared to a soluble rE antigen mix.
Discussion
A safe and efficacious vaccine that protects against all 4 DENV serotypes is urgently needed,
but so far, results with leading live-attenuated tetravalent vaccine candidates are mixed. While
Fig 5. Tetravalent NP-rE immunization induces robust neutralizing IgG responses. A) DENV1-4 specific IgG responses were determined for week 3, 4, 8, 10 and 16.
B) DENV1-4 specific IgG end-point dilution titers (EPD) for total IgG, IgG1 and IgG2a were determined for week 16 sera. C) The neutralizing activity of the mice sera
at week 16 was determined with a neutralization assay where DENV is incubated with serially diluted mice sera and subsequently allowed to infect Vero-cells.
Neutralizing activity was expressed as the dilution where 50% of the virus was neutralized (Neut50). Statistical differences were determined by one-way ANOVA
followed by Tukeys test (p<0.05).
https://doi.org/10.1371/journal.pntd.0006793.g005
the leading candidate developed by Sanofi Pasture is efficacious in people with pre-existing
immunity to DENVs prior to vaccination, the vaccine is contraindicated in naïve individuals
because of poor efficacy and safety [40]. The unbalanced replication of vaccine virus strains is
Fig 6. Tetra NP-rE induces serotype specific IgG responses in a tetravalent background. A DENV rE depletion assay was used to estimate the proportions of
serotype-specific and cross-reactive antibody panels in sera of mice immunized with tetravalent vaccine formulations. Serum was incubated with magnetic beads coated
with rE of DENV1, 2, 3 or 4 and serotype specific IgG titers were determined against all 4 rE serotypes for A) TR and B) TNR tetravalent formulations. For example, to
establish complete exhaustion (red bars) of all serotype-specific and cross-reactive DENV1 binding antibodies, sera was depleted with DENV1 rE. To determine the
DENV1 serotype-specific portion (green bars), the same sera was depleted with DENV2, 3 and 4 rE. A negative control or handling control depletion (yellow bars) was
performed using maltose binding protein (MBP). Statistical differences were determined by one-way ANOVA followed by Tukeys test (p<0.05).
https://doi.org/10.1371/journal.pntd.0006793.g006
Fig 7. DENV rE particulation enhances serotype specificity in tetravalent formulations. To determine the portion of serotype-specific neutralizing antibodies,
sera from A) TR and B) TNR immunized mice were depleted from serotype-specific and cross-reactive (red lines), cross-reactive (green lines) neutralizing
antibodies. Serum neutralization was determined using a flow based approach where serially diluted serum was incubated with virus, which was subsequently
allowed to infect vero-cells. Neutralizing capacity of the sera is expressed as Neut50 values, indicating the serum dilution where 50% of the virus is neutralized
(Table 1).
https://doi.org/10.1371/journal.pntd.0006793.g007
the most likely explanation for the poor performance in naïve individuals [41]. Multi-compo-
nent protein subunit vaccines are a promising alternative strategy to induce balanced immu-
nity to all 4 serotypes but soluble antigens are poor immunogens compared to virions. Here
we demonstrate that nanoparticles displaying rE from each serotype are a promising alterna-
tive to live virus vaccines.
In previous studies we have shown that adsorbing DENV2 rE to PLGA nanoparticles of
80 × 320 nm increased specific IgG and neutralizing antibody titers compared to the soluble
rE protein alone [15]. In this study, we first evaluated nanoparticle delivery of the other three
DENV serotypes in monovalent formulations. For DENV1, 2 and 4 we saw enhanced levels of
serotype specific (TS) IgG and neutralizing antibodies when rE proteins were delivered using
PLGA nanoparticles compared to soluble antigen. DENV3 rE appeared to be highly immuno-
genic as a soluble protein, so a particulation effect was not observed. Since all mice were inocu-
lated with 5 μg of antigen, adsorbed to particles or as a soluble antigen, a lower DENV3 rE
dose might reveal increased responses in the particle groups. This would require further dose
optimization.
DENV1-4 rE proteins were evaluated as tetravalent soluble or particulate vaccines in mice.
While both the soluble and particulate vaccines induced similar levels of neutralizing antibody,
possibly due to an increase of cross-reactive antibody levels, we observed differences in IgG
isotypes being induced. Where soluble antigens promote a predominant Th2 response by the
induction of IgG1, particulate antigens stimulated a more balanced IgG1/IgG2a and thus Th1/
Th2 response. In addition, we observed qualitative differences in the properties of neutralizing
antibodies induced by each vaccine formulation. Though limited by the quantity of sera,
serum depletion studies revealed a trend that the proportion of DENV serotype specific neu-
tralizing antibodies increased when rE was adsorbed to PLGA surfaces compared to the solu-
ble vaccine. This effect was especially clear for DENV1, and DENV4, where the serotype
specific neutralizing antibody response against DENV1 increased from 6.1% to 22.8% and for
DENV4 from 43.1% to almost 98%. Due large quantity of immune sera required for antibody
depletion studies, we had to pool immune sera from all the animals within each group for
these experiments, which precluded statistical analysis of the differences between groups.
While neutralizing antibodies have been long considered to be a surrogate of protective
immunity in flavivirus vaccine development, the Sanofi clinical trial with Dengvaxia has clearly
established that people with high levels of neutralizing antibodies can experience DENV infec-
tions [39,42]. The Sanofi experience and other studies point to both the level and quality of
neutralizing antibodies as critical determinants of protective immunity [43,44]. In particular,
in naïve individuals who are vaccinated, serotype-specific neutralizing antibodies appears to
be critical for protection [39] [44]. Even though DENV rE subunit antigens have not been par-
ticularly promising as vaccine antigens [16], here we show that both the level and quality of
neutralizing antibodies can be enhanced by using nanoparticles to deliver DENV monovalent
and tetravalent rE proteins. The efficacy of subunit based dengue vaccines is expected be
increased by the expression of quaternary epitopes recognized by strongly neutralizing anti-
bodies. Although rE subunits are lacking these E-dimer dependent epitopes, we have previ-
ously developed methods to assemble E-dimers out of soluble monomers [37]. Future studies
will focus on displaying quaternary epitopes carrying E-protein subunits on nanoparticles sur-
faces. In addition, our nanoparticles vaccine platform requires further evaluation of adjuvants
to enhance the immunogenicity of particulated rE antigens. More broadly, a further developed
platform described here for DENV vaccines can be modified to develop vaccines for other fla-
viviruses such as West Nile, yellow fever virus or Zika viruses.
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